Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q2 2022 Earnings Presentation
17 slides from Arcticzymes Technologies Asa's earnings presentation, 2022
Slide 1: Q2 2022
Q2 2022
Slide 2: Agenda
Agenda 1 Highlights – Q2 2022 2 Business Update 3 Financials 4 Outlook 2022 and Beyond
Slide 3: Highlights
Highlights
Slide 4: Highlights Q2 2022
Highlights Q2 2022 Growth trend continues Appointed a new VP Achieved growth in Growth continues in of Bus. Dev. and quarterly sales Molecular Tools and Marketing 30.4 MNOK Biomanufacturing Dirk Hahneiser Initiated the EBITDA establishment of a performance Drug Master File 9.5 MNOK (DMF) 4
Slide 5: Business Update
Business Update
Slide 6: Business Updates: Commercial
Business Updates Commercial Biomanufacturing Molecular Tools (Research & Diagnostics) ✓ Quarterly sales 14.8 MNOK (78% growth) ✓ Quarterly sales 15.5 MNOK (18% growth) ✓ Accounts for 49% of total Q2 sales ✓ Accounts for 51% of total Q2 sales ✓ Upturn in sales following pandemic continues ✓ Research
Slide 7: Business Updates: Geographical Sales Contribution
Business Updates Commercial Geographical Sales Contribution Global Reach Strengthened Americas EMEA APAC 2021 39 % 48 % 13 % Q1 Americas EMEA APAC 2022 41 % 46 % 13 % Q2 Americas EMEA AP. 2022 39 % 52 % 9% • China: Sales hampered by Coronavirus lockdowns and • Appointed Dirk Hahneiser as VP of Bus.
Slide 8: Business Updates: Innovations and Operations
Business Updates Innovations and Operations New Applications Lab - Oslo Manufacturing facility - Tromsø Innovations Operations ✓ Applications Lab in Oslo (ShareLab) ✓ New production facility continues to increase capacity ✓ Successfully hired 2 applications scientist through the incremental recruitm
Slide 9: Business Updates: Strategic Growth Initiatives
Business Updates Strategic Growth Initiatives AZT remains committed to execute on its strategic growth initiatives Organic growth Ongoing recruitment drive to strengthen the organisation cross functionally continues Greater competences/support in quality, regulatory, project management, cGMP product
Slide 10: Financials
Financials
Slide 11: Sales
Sales Currency impacts underlying growth positively Biomanufacturing 35 Molecular Tools Sales increase of 43 % compared to same 30 quarter last year Achieved 30.4 MNOK (21.3 MNOK) 25 Currency had an estimated 2.5 MNOK Sales in MNOK 20 positive impact on underlying sales growth in Q2 and NOK 3.1 MNOK
Slide 12: 12 month rolling average quarterly sales
12 month rolling average quarterly sales Growth trend continues 40 Sales development 35 Sales development ex Covid-19 30 25 MNOK 20 15 10 5 0 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 12 *not reporting on Covid-19 sales separately
Slide 13: Profitability and expenses
Profitability and expenses Investments in organic growth influences our figures 60 Sales 50 EBITDA Sales Q2 - MNOK 30.4 vs. 21.3 (+43%) 40 YTD - MNOK 79.5 vs 62.2 (+28%) MNOK 30 EBITDA Q2 - MNOK 9.5 vs 6.0 (+58%) 20 YTD - MNOK 37.4 vs 31.8 (+18%) 10 Expenses increased by 4.5 MNOK in Q2 0 External su
Slide 14: Cash flow
Cash flow +16 MNOK in positive cash flow for Q2 240 30 Net Cash (MNOK) 230 Changes in Cash (MNOK) 25 220 210 20 Changes in cash (MNOK) Net Cash (MNOK) 200 15 190 180 10 170 5 160 150 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 14
Slide 15: Outlook
Outlook
Slide 16: Outlook 2022 and Beyond
Outlook 2022 and Beyond Annual Sale Target Remains unchanged The Company outlook for 2022 51% achieved Annual sales target of NOK 155 million Quarterly fluctuations will continue Lower contribution from coronavirus-related sales Expanded innovation activities into the Oslo region Quarterly Rolling 1
Slide 17: Thank you Q&A Session
Thank you Q&A Session arcticzymes.com
ArcticZymes Technologies — Q2 2022 Earnings Presentation on 6ix